Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical <i>SMN1</i> and <i>SMN2</i> Gene-Specific Sequencing to Enhance the Clinical Sensitivity of Spinal Muscular Atrophy Diagnostic Testing.

Human mutation·2025
Same author

Distinct rates of VUS reclassification are observed when subclassifying VUS by evidence level.

Genetics in medicine : official journal of the American College of Medical Genetics·2025
Same author

Distinct rates of VUS reclassification are observed when subclassifying VUS by evidence level.

medRxiv : the preprint server for health sciences·2024
Same author

Expanding the Phenotype of Extremely Early Onset Juvenile Huntington's Disease: A Case Report and Review of Previously Published Cases.

American journal of medical genetics. Part A·2024
Same author

Clinical characterization of the mutational landscape of 24,639 real-world samples from patients with myeloid malignancies.

Cancer genetics·2023
Same author

The landscape of reported VUS in multi-gene panel and genomic testing: Time for a change.

Genetics in medicine : official journal of the American College of Medical Genetics·2023

Related Experiment Video

Updated: Jun 1, 2026

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)

Published on: March 17, 2012

Technical standards and guidelines for spinal muscular atrophy testing.

Thomas W Prior1, Narasimhan Nagan, Elaine A Sugarman

  • 1Department of Pathology, Ohio State University, 1645 Neil Ave, Columbus, OH 43210, USA. Thomas.prior@osumc.edu

Genetics in Medicine : Official Journal of the American College of Medical Genetics
|June 16, 2011
PubMed
Summary
This summary is machine-generated.

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder caused by SMN1 gene mutations. Genetic testing for SMN1 gene deletions is crucial for diagnosing SMA and identifying carriers.

More Related Videos

Manual Muscle Testing: A Method of Measuring Extremity Muscle Strength Applied to Critically Ill Patients
09:44

Manual Muscle Testing: A Method of Measuring Extremity Muscle Strength Applied to Critically Ill Patients

Published on: April 12, 2011

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy
10:02

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy

Published on: November 3, 2016

Related Experiment Videos

Last Updated: Jun 1, 2026

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)

Published on: March 17, 2012

Manual Muscle Testing: A Method of Measuring Extremity Muscle Strength Applied to Critically Ill Patients
09:44

Manual Muscle Testing: A Method of Measuring Extremity Muscle Strength Applied to Critically Ill Patients

Published on: April 12, 2011

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy
10:02

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy

Published on: November 3, 2016

Area of Science:

  • Genetics
  • Neurology
  • Molecular Biology

Background:

  • Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder affecting motor neurons.
  • It is caused by mutations in the survival motor neuron (SMN1) gene, impacting motor function.
  • SMA prevalence is approximately 1 in 10,000 live births.

Purpose of the Study:

  • To provide a checklist for genetic testing professionals regarding SMA diagnosis and carrier detection.
  • To outline standards and guidelines for clinical laboratory analysis of SMA.
  • To detail the genetic basis and diagnostic approaches for SMA.

Main Methods:

  • Analysis of SMN1 gene mutations, specifically homozygous absence of SMN1 exon 7.
  • Determination of SMN1 gene copy number for carrier detection.
  • Utilizing established Standards and Guidelines for Clinical Laboratories.

Main Results:

  • Homozygous absence of SMN1 exon 7 is a reliable diagnostic marker for SMA.
  • The number of SMN2 gene copies influences the clinical phenotype of SMA.
  • Accurate SMN1 gene copy determination is essential for carrier screening.

Conclusions:

  • Genetic testing for SMN1 gene alterations is fundamental for SMA diagnosis.
  • Understanding SMN gene structure (SMN1 and SMN2) is key to interpreting SMA phenotypes.
  • Standardized genetic testing protocols ensure accurate diagnosis and carrier identification for SMA.